News Zentiva set to change hands in €4.1bn private equity deal Ex-Sanofi generics company Zentiva is poised for a sale by current owner Advent International to US investment group GTCR, says a media report.
News Did AZ scupper Sobi's $8bn private equity buyout? An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, with reports suggesting AstraZen
News Sanofi in final stages of negotiation in sale of generics ar... Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.